HC Wainwright & Co. Maintains Buy on Opus Genetics, Raises Price Target to $14

Benzinga · 2d ago
HC Wainwright & Co. analyst Matthew Caufield maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $8 to $14.